We are live on
!
Find out more
Glenview Capital Management Portfolio holdings
AUM
$5.49B
Turnover
46.55%
1-Year Est. Return
46.89%
This Fund
S&P 500
This Quarter
Est. Return
+30.41%
1 Year Est. Return
+46.89%
3 Year Est. Return
+94.27%
5 Year Est. Return
+129.04%
10 Year Est. Return
+529.98%
AUM
$5.49B
AUM Growth
+$1.51B
(+38%)
Cap. Flow
+$309M
Cap. Flow
% of AUM
5.62%
Top 10 Holdings %
Top 10 Hldgs %
60.68%
Holding
58
New
14
Increased
15
Reduced
15
Closed
13
Avg Time Held Equity + Options
1.7
years
Top 10 Avg Time Held Equity + Options
1.6
years
Top 20 Avg Time Held Equity + Options
1.2
years
Avg Time Held Equity only
1.8
years
Top 10 Avg Time Held Equity only
1.8
years
Top 20 Avg Time Held Equity only
1.3
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Agilent Technologies
A
|
+$240M |
| 2 |
Thermo Fisher Scientific
TMO
|
+$181M |
| 3 |
Danaher
DHR
|
+$180M |
| 4 |
Global Payments
GPN
|
+$175M |
| 5 |
Meta Platforms (Facebook)
META
|
+$143M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
CVS Health
CVS
|
+$301M |
| 2 |
Advanced Micro Devices
AMD
|
+$144M |
| 3 |
DXC Technology
DXC
|
+$112M |
| 4 |
ZoomInfo Technologies
GTM
|
+$95.1M |
| 5 |
Centene
CNC
|
+$71M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 49.86% |
| 2 | Industrials | 12.99% |
| 3 | Technology | 12.58% |
| 4 | Consumer Discretionary | 9.03% |
| 5 | Miscellaneous | 8.84% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
26
Cisco
CSCO
$424B
| $48.5M | 0.88% |
413,332
+73,513
| +22% | +$7.69M |
2026 Q1
1 quarter
|
|
27
Element Solutions
ESI
$8.53B
| $47.5M | 0.86% |
994,579
-634,104
| -39% | -$26.3M |
2016 Q3
39 quarters
|
|
28
Applied Materials
AMAT
$331B
| $47.1M | 0.86% |
65,201
-132,008
| -67% | -$60.9M |
2025 Q4
2 quarters
|
|
29
MKS Inc
MKSI
$14.9B
| $43.8M | 0.8% |
+98,532
| New | +$30.8M |
2026 Q2
0 quarters
|
|
30
Cedar Fair
FUN
$847M
| $43M | 0.78% |
2,017,821
-205,328
| -9% | -$4.19M |
2025 Q4
2 quarters
|
|
31
STMicroelectronics
STM
$41B
| $41.9M | 0.76% |
+560,060
| New | +$33.7M |
2026 Q2
0 quarters
|
|
32
AbbVie
ABBV
$503B
| $37.5M | 0.68% |
+148,913
| New | +$32M |
2026 Q2
0 quarters
|
|
33
AstraZeneca
AZN
$256B
| $34.9M | 0.64% |
+184,279
| New | +$34.7M |
2026 Q2
0 quarters
|
|
34
Bausch + Lomb
BLCO
$5.82B
| $31.8M | 0.58% |
1,918,148
+7,652
| +0.4% | +$122K |
2025 Q1
5 quarters
|
|
35
Baker Hughes
BKR
$55.4B
| $27.4M | 0.5% |
493,519
+189,844
| +63% | +$12M |
2026 Q1
1 quarter
|
|
36
Elevance Health
ELV
$92.8B
| $25.8M | 0.47% |
+66,599
| New | +$24.7M |
2026 Q2
0 quarters
|
|
37
Microchip Technology
MCHP
$40.3B
| $24.2M | 0.44% |
+265,577
| New | +$23.7M |
2026 Q2
0 quarters
|
|
|
38
CALL
Agilent Technologies
A
$48.7B
| $15.5M | 0.28% |
+116,600
| New | +$14.2M |
2026 Q2
0 quarters
|
|
39
Bruker
BRKR
$8.37B
| $15.2M | 0.28% |
+252,169
| New | +$11.8M |
2026 Q2
0 quarters
|
|
40
Novartis
NVS
$287B
| $13.6M | 0.25% |
+86,909
| New | +$13M |
2026 Q2
0 quarters
|
|
41
DigitalOcean
DOCN
$11.4B
| $13.3M | 0.24% |
84,812
-165,188
| -66% | -$22.3M |
2025 Q4
2 quarters
|
|
42
Primo Brands
PRMB
$7.05B
| $9.9M | 0.18% |
404,971
-126,080
| -24% | -$2.8M |
2026 Q1
1 quarter
|
|
43
Boston Scientific
BSX
$63.9B
| $4.83M | 0.09% |
+113,096
| New | +$6.14M |
2026 Q2
0 quarters
|
|
44
Cardinal Health
CAH
$58.5B
| $4.28M | 0.08% |
+18,018
| New | +$3.74M |
2026 Q2
0 quarters
|
|
45
Bio-Techne
TECH
$11.4B
| $4.12M | 0.08% |
58,324
-127,988
| -69% | -$6.91M |
2025 Q3
3 quarters
|
|
46
Akamai
AKAM
$12.6B
| – | – |
-156,453
| Closed | -$18M | – |
|
47
Biogen
BIIB
$34.7B
| – | – |
-57,019
| Closed | -$10.5M | – |
|
|
48
DXC Technology
DXC
$2.15B
| – | – |
-8,895,875
| Closed | -$112M | – |
|
|
49
CALL
Global Payments
GPN
$22.1B
| – | – |
-100,000
| Closed | -$6.73M | – |
|
50
Intel
INTC
$481B
| – | – |
-399,506
| Closed | -$17.6M | – |
|
Similar funds
MC
SCM
Glenview Capital Management's Q2 2026 Portfolio in Review
As of Q2 2026, Glenview Capital Management held 58 positions worth $5.49B, up 38% from $3.98B the previous quarter. Its ten largest holdings account for 61% of the portfolio.
Glenview Capital Management deployed $309M of net new capital in Q2 2026, opening 14 new positions and adding to 15 existing holdings. Its largest new stake was Agilent Technologies: 1,969,541 shares worth $262M.
By sector, the portfolio is most concentrated in Healthcare at 50% of assets, up from 45% a quarter earlier, followed by Industrials and Technology.
On the sell side, the largest reduction was CVS Health, an estimated $301M trimmed.
- Glenview Capital Management's largest Q2 2026 buy was Agilent Technologies: 1,969,541 shares worth $262M.
- Glenview Capital Management added most to Thermo Fisher Scientific in Q2 2026, an estimated $181M increase.
- Glenview Capital Management's biggest Q2 2026 reduction was CVS Health, cutting an estimated $301M.
- Glenview Capital Management fully exited DXC Technology in Q2 2026, selling an estimated $112M.
- Glenview Capital Management's ten largest holdings make up 61% of its $5.49B portfolio in Q2 2026.
- Glenview Capital Management opened 14 new positions and closed 13 in Q2 2026.
- Glenview Capital Management's portfolio value rose 38% quarter-over-quarter to $5.49B.
Based on Glenview Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.